13.14
1.22 (10.23%)
| Penutupan Terdahulu | 11.92 |
| Buka | 11.84 |
| Jumlah Dagangan | 3,707,305 |
| Purata Dagangan (3B) | 4,197,458 |
| Modal Pasaran | 1,743,526,784 |
| Harga / Buku (P/B) | 12.19 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| EPS Cair (TTM) | -9.25 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 13.68% |
| Nisbah Semasa (MRQ) | 2.33 |
| Aliran Tunai Operasi (OCF TTM) | -644.94 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -394.10 M |
| Pulangan Atas Aset (ROA TTM) | -129.99% |
| Pulangan Atas Ekuiti (ROE TTM) | -316.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Biohaven Ltd. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.00 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 11.96% |
| % Dimiliki oleh Institusi | 90.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Sep 2025 | 5,620,271 |
| Bellevue Group Ag | 30 Sep 2025 | 2,802,853 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 22.00 (RBC Capital, 67.43%) | Beli |
| Median | 15.00 (14.16%) | |
| Rendah | 9.00 (Bernstein, -31.51%) | Pegang |
| Purata | 14.89 (13.32%) | |
| Jumlah | 6 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 9.68 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 21 Jan 2026 | 22.00 (67.43%) | Beli | 12.87 |
| 06 Nov 2025 | 9.00 (-31.51%) | Pegang | 8.53 | |
| Morgan Stanley | 06 Jan 2026 | 21.00 (59.82%) | Beli | 9.62 |
| 18 Nov 2025 | 26.00 (97.87%) | Beli | 9.45 | |
| HC Wainwright & Co. | 26 Dec 2025 | 11.00 (-16.29%) | Pegang | 11.15 |
| 03 Dec 2025 | 11.00 (-16.29%) | Pegang | 9.12 | |
| UBS | 26 Nov 2025 | 11.00 (-16.29%) | Pegang | 9.48 |
| JP Morgan | 20 Nov 2025 | 15.00 (14.16%) | Beli | 9.63 |
| BTIG | 18 Nov 2025 | 16.00 (21.77%) | Beli | 9.45 |
| 06 Nov 2025 | 16.00 (21.77%) | Beli | 8.53 | |
| Citigroup | 13 Nov 2025 | 14.00 (6.54%) | Beli | 8.08 |
| Bernstein | 06 Nov 2025 | 9.00 (-31.51%) | Pegang | 8.53 |
| TD Cowen | 05 Nov 2025 | 15.00 (14.16%) | Beli | 8.34 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |